Abbisko’s pimicotinib at FDA: reading the China-to-Merck path

The first read of Abbisko’s U.S. approval for pimicotinib is clinical: an oral CSF-1R inhibitor for symptomatic tenosynovial giant cell tumor (TGCT). The sharper industry read is structural. A China-origin asset, developed by Abbisko (HKEX: 2256), is now commercialized worldwide by Merck KGaA, Darmstadt, Germany—and the economics that matter to BD and capital desks were largely locked in years before the FDA stamp.

What moved

On 10 November 2026, the FDA approved pimicotinib (brand PIMJETMI; EMD Serono is the U.S./Canada healthcare business of Merck KGaA) for adults with symptomatic TGCT for which surgical resection may cause worsening functional limitation or severe morbidity, according to the agency’s approval notice. Abbisko’s Hong Kong Stock Exchange filing and joint communications with Merck frame the U.S. decision as the fourth major-market approval after China NMPA (December 2025), Health Canada (June 2026), and Swissmedic (October 2026).

TGCT is a rare, locally aggressive tumor of joints, tendon sheaths, and bursae. It is driven by CSF-1 overexpression and CSF-1R–expressing inflammatory-cell accumulation—the biological rationale for CSF-1R blockade, as Merck/EMD Serono’s PIMJETMI materials restate. Pharmacy Times coverage has described pimicotinib as among a small set of CSF-1R–targeted systemic options in this niche.

How to read the evidence, not the adjectives

Approval rests on the global Phase 3 MANEUVER study (NCT05804045) plus longer-term follow-up. FDA’s summary is more precise than most WeChat rewrites:

• International, double-blind, randomized 2:1 to pimicotinib 50 mg once daily or placebo; stratified by region (China vs non-China).
• Eligible patients had symptomatic TGCT with measurable disease (at least one lesion ≥2 cm) and were candidates for systemic therapy; the program excluded prior anti–CSF-1/CSF-1R therapy, per FDA and Abbisko HKEX trial descriptions.
• Primary endpoint: overall response rate (ORR) at week 25 by blinded independent central review per RECIST v1.1.
• ORR was 56% (95% CI 42–68) on pimicotinib versus 3.2% (95% CI 0.1–17) on placebo in the FDA write-up. (Earlier topline communications had cited 54.0% vs 3.2%; use the FDA label math for U.S. diligence.)
• Median duration of response was not reached; among responders, 91% had DOR ≥6 months and 77% ≥12 months in the FDA write-up. Company/ESMO longer-term messaging similarly said most week-25 responders (77%) kept clinical benefit after another year of follow-up (median follow-up 14.3 months in patients first randomized to drug).
• Statistically significant gains versus placebo at week 25 on functional and patient-reported endpoints: active range of motion, Brief Pain Inventory worst-pain NRS, and PROMIS physical function.

Enrollment was deliberately global. Abbisko and Merck have described roughly 94 patients in Part 1, with China and Western sites both material (company materials have cited on the order of 45 patients in China and the balance across the U.S., Canada, and Europe). That design matters commercially: it reduces the “China-only Phase 3” discount that still hangs over many outbound assets.

Regulatory process also carried a coordination signal. Abbisko says U.S., Canadian, and Swiss filings moved under FDA Oncology Center of Excellence’s Project Orbis framework; EMA had granted PRIME designation earlier in the program’s European path.

How to read the deal—not only the stamp

The commercial owner is Merck KGaA. The path was staged, as set out in Abbisko’s HKEX collaboration filings and Merck’s December 2023 / 2025 option communications:

1. December 2023: exclusive commercialization license for Mainland China, Hong Kong, Macau, and Taiwan, plus an exclusive option for rest-of-world commercial rights; Abbisko kept development lead on the TGCT program. Upfront: USD 70 million.
2. April 2025: Merck exercised the worldwide commercialization option for an USD 85 million option fee (received around May 2025). Combined cash already booked from upfront + option: USD 155 million.
3. Economics still ahead: Abbisko is eligible for up to USD 605.5 million in aggregate payments (upfront, option fee, development and commercial milestones) plus double-digit tiered royalties on net sales. On the FDA approval specifically, Abbisko’s HKEX release states a further USD 20 million milestone on first commercial sale in the United States, alongside double-digit royalties on global net sales and other milestones.

That stack is the BD lesson. By the time the FDA letter lands, Abbisko’s residual risk is mostly partner execution—U.S. specialty launch, pricing, and conversion of labels into royalty-bearing sales—not whether a China biotech can field its own American sales force for a rare orthopedic oncology niche.

What it means for industry readers

• BD and partnering teams: Keep the slide simple—China originator, multinational commercial owner, global Phase 3 with China and Western enrollment, Project Orbis multi-agency path, cash already taken on license/option, milestone on first U.S. sale. Ask counterparties for the same clarity: who books the sale, what triggers cash, what remains contingent.
• Investors following China biotech: Separate “approval theater” from “cash visibility.” The next observable is not another press release adjective; it is first U.S. commercial sale (and the USD 20 million trigger) and how Abbisko guides the remaining milestone book.
• Wider industry readers: TGCT is small. The transferable pattern is larger: focused rare-disease endpoint, oral small molecule, staged China-then-global commercial license with a priced option, then sequential major-market stamps.

Limits

This note does not forecast peak sales, rank every CSF-1R competitor, or offer clinical advice. The facts above track the FDA’s approval summary, Abbisko’s HKEX disclosures, and Merck/EMD Serono communications—not secondary rewrites.

China Pharma Desk analysis. Industry information only—not medical or investment advice.